To prevent cervical cancer, a governmentfunded vaccination programme against human papillomavirus (HPV) infection started in New Zealand in 2008. After an initial catch-up phase, vaccination with a quadrivalent vaccine was routinely offered from year 2011 onwards to girls in school year 8 (typically age 12 years) or in primary care settings at age 12.
To better understand the impact of this vaccination programme, we examined national prescription data from the government's pharmaceutical purchasing agency (PHARMAC). From this agency, we obtained national data for both imiquimod cream (ie, Aldara) and for podophyllum resin-based products These reductions in prescriptions are entirely consistent with other evidence for beneficial HPV vaccination impacts (ie, reduced number of first presentations for genital warts seen in sexual health clinics for both young women and men in New Zealand). This pattern is also consistent with declining population burdens of genital warts after vaccination programmes were introduced in Australia and Sweden.
Finally, this brief analysis also further supports the potential use of pharmaceutical data for evaluating HPV prevention programmes, as also performed in Sweden. 
